Guardian Pharmacy Services, Inc. · NYSE:GRDN
Guardian Pharmacy Services — Investor Presentation (October 2026)
29 slides from Guardian Pharmacy Services's investor presentation, October 2026
Slide 1: Smarter Growth, Better Service
Smarter Growth, Better Service Investor Deck – October 2026 Guardian Pharmacy Services 2026 | 1
Slide 2: Disclaimers
Disclaimers Forward-Looking Statements: This presentation (including oral commentary that accompanies this presentation) has been prepared by Guardian Pharmacy Services, Inc. (“Guardian,” the “Company,” “we” or “us”) and contains forward-looking statements. Forward-looking statements are all stateme
Slide 3: Management team
Fred Burke David Morris Will Mudd Kendall Forbes shley Stockton Ashley Stockton President, CEO, Co-founder David Morris Head of Investor Relations VP, Investor Relations EVP, COO, Co-founder EVP, Sales andCFO SVP, Operations EVP, CFO, Co-founder • Co-founded Guardian Pharmacy • Co-founded Guardian P
Slide 4: Guardian: A Differentiated LTC Pharmacy Services Company
Guardian: A Differentiated LTC Pharmacy Services Company Transforming Medication Management for Seniors in Assisted Living Facilities (ALF) Who is Guardian? Our Solution? ALFs need dedicated medication Purpose-built to provide medication A leading provider of ALF care and coordination - rising pharm
Slide 5: Guardian's Proven Model: Scaled, Profitable, Resilient
Guardian’s Proven Model: Scaled, Profitable, Resilient Multi-pronged growth strategy focused on expanding market share: Secular growth, organic growth, and disciplined M&A Scalable platform with key profitability levers, optimized by data analytics: Purchasing, reimbursement, and national account le
Slide 6: Leading the Way in ALF
Leading the Way in “ALF” Assisted Living Facilities Guardian Pharmacy Services 2026 | 6
Slide 7: Focused on Highly Attractive ALF Market
Focused on Highly Attractive ALF Market ALF & Memory Care Pharmacy Market ~$7 Billion Projected Population Growth 80+ Year-Olds(2) Large Existing Market Opportunity (1) (in millions) 1,000,000+ Residents 24 Secular Tailwind 22 Increasing occupancy/aging population 20 Highly Fragmented Market 18 1,20
Slide 8: Medication Management - Top Driver for Entering an ALF
Medication Management - Top Driver for Entering an ALF Rising Age and Acuity Require a Healthcare-Focused Approach ALF Resident Characteristics ALF Resident Characteristics • Age is rising - ~85 years old • Financially capable • ~22 month stay (median) • High acuity Key Reasons for Transitioning to
Slide 9: Built for the Unique Needs of ALF
Built for the Unique Needs of ALF More than a Pharmacy – A Medication Care Coordination Partner in ALF Drug Regimen Review Proper Formulary Refill Authorization Compliance Packaging Facilitate Drug Administration Training/Compliance Consulting Guardian Revenue By Payor Type (2025) Guardian Pharmacy
Slide 10: A Market Leader
Large # of A Market Leader Residents Served(1) Unique and Scalable Model ~205,000+ Total Residents Local Service Model + Strong Centralized Support Volumes/Scale ~29 mm Prescriptions(1) High ALF Market Share Adoption Rates 13% Nationwide(2) ~90%(1) (1) As of December 31, 2025. (2) Based on NIC MAP®
Slide 11: ALF & Memory Care Market Share – 13% Nationwide
ALF & Memory Care Market Share – 13% Nationwide National Reach, Local Impact 56 Pharmacy Locations(1) Market Share by State(2) 65% Most Mature Pharmacy 60% 55% 50% Large opportunity ahead for 45% continued market share gains in 40% existing states 35% 30% Average 25% 20% 15% 10% 5% 0% (1) Location o
Slide 12: Favorable Competitive Landscape/High Barriers to Entry
Favorable Competitive Landscape/High Barriers to Entry Competitors Institutional Independent Pharmacies Pharmacies Skilled Nursing (SNF) Focused/Centralized Strong Local Service/Less Profitable High Barriers to Entry • Large Investments • Leadership/talent build • Long timeline to profitability • Re
Slide 13: Growth Levers
Growth Levers Organic + Acquisitions Guardian Pharmacy Services 2026 | 13
Slide 14: Multiple Organic Growth Drivers
Multiple Organic Growth Drivers Organic Growth Drivers LAUNCH GREENFIELD STARTUPS INCREASE ADOPTION RATES ADD NEW FACILITIES Guardian Pharmacy Services 2026 | 14
Slide 15: Organic Growth – Greenfield Start-Ups
Organic Growth – Greenfield Start-Ups Expansion into Adjacent and New Underserved and Growth Markets Growth seeded by existing residents in contiguous pharmacy market Recent Greenfields (2020-2026) 21 Greenfields(1) 2026 Cincinnati Lexington 2025 SW + SE Florida Naples 2024 Cincinnati Columbus 2024
Slide 16: Acquisitions
Acquisitions Measured and Strategic Approach to M&A Guardian’s Priority Geography Typical Target Size • A leader who can develop the local • Answer national ALF demand • ~$10 - $30 mm revenue team to manage growth • Fill white spaces in growth markets • ~1,500 - 3,000 residents • An operator who see
Slide 17: M&A/Greenfield Goal: Targeted Level of Accretion by Year 4
M&A/Greenfield Goal: Targeted Level of Accretion by Year 4 TIMELINE TO ACCRETION Year 1 Year 2-3 Year 4+ Core functions set foundation for future profitability: build teams, integrate Profitability improves Margins approach corporate average systems POINTS OF LEVERAGE Margin Management Reimbursement
Slide 18: Acquisition & Greenfield Impact Opportunity
Acquisition & Greenfield Impact Opportunity Multiple Locations Projected to Achieve Targeted Accretion Ahead High single-digit organic Pharmacies collectively operating growth at targeted operating COVID-19 Pandemic @ ~breakeven margin 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 • Cincinnati,
Slide 19: Competitive Advantage: Service & Technology
Competitive Advantage Service & Technology Guardian Pharmacy Services 2026 | 19
Slide 20: Integrated Ecosystem – Service Led, Data-Driven
Integrated Ecosystem – Service Led, Data-Driven Clinical Intelligence Powering Financial Optimization and Better Outcomes “Financial Engine” “Clinical Brain” Drive Margin Improvement Improve Resident Outcomes • Purchasing • Clinical interventions • Reimbursement optimization • Regimen optimization •
Slide 21: Better Outcomes, Lower Costs
Better Outcomes, Lower Costs Appropriate Drug Regimen Clinical Interventions Benefit Optimization Savings ~100,000(1) $56mm(1) Savings to Residents Allergies, Duplicate Meds, Drug-Drug Interactions, Clarification, Medication Reconciliation (1) For full-year 2025. Guardian Pharmacy Services 2026 | 21
Slide 22: Smarter Tech, Better Service
Smarter Tech, Better Service Proprietary Ecosystem Amplified by Supporting Technology Promotes accurate and efficiency Advanced Robotics medication dispensing Promotes Adherence and Compliance + eMAR integration with ALF Near 100% Guardian Pharmacy Services 2026 | 22
Slide 23: Powerful Partner to the Payors (PBMs & Health Plans)
Powerful Partner to the Payors (PBMs & Health Plans) Helping to Improve Adherence Scores and Network Adequacy Benefits to Payors What Guardian Does Benefits Everyone (PBMs/Health Plans) Optimizes drug regimen: Receive Rebates (mfr.) • 11 11 states Clinical and • Interventions Reduce Adverse Events •
Slide 24: Financial Performance
Financial Performance Consistent Execution & Results Guardian Pharmacy Services 2026 | 24
Slide 25: Consistent Track Record of Growth
Consistent Track Record of Growth $1,500 Revenue Adjusted EBITDA $1,449 $125 $1,350 $115 $115 $1,228 ~15% $1,200 $105 Revenue - 5 Year CAGR Adjusted EBITDA ($ in millions) $1,046 Revenue ($ in millions) $1,050 $95 $909 $91 $900 ~16% $85 $792 Adjusted EBITDA - 5 Year CAGR $736 $750 $698 $76 $75 $600
Slide 26: Resident and Prescription Growth
Resident and Prescription Growth Resident Count Prescription Growth (in thousands) (in millions) 205 186 29 163 151 24 22 20 (1) 2022 2023 2024 2025 2022 2023 2024 2025 (1) Organic Acquired (1) For Full Year 2025. Guardian Pharmacy Services 2026 | 26
Slide 27: Strong Cash Flow and Stewards of Capital
Strong Cash Flow and Stewards of Capital Return focused Steady Cash Build ($ in millions) 100 90 80 70 ~60% 60 Cash Conversion(1) 50 40 30 20 10 0 2024 2025 YTD 2026 (1) Cash conversion for full year 2025. Defined as Adjusted EBITDA ($115 million) minus capex ($19.6 million) and taxes ($24.5 million
Slide 28: Appendix
Appendix Guardian Pharmacy Services 2026 | 28
Slide 29: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA ($ in millions) 2020 2021 2022 2023 2024 2025 Net Income $30 $28 $50 $38 ($71) $49 Add: Interest Expense, Net $2 $2 $2 $3 $3 ($0) Depreciation & Amortization $17 $17 $17 $18 $20 $22 Taxes $0 $0 $0 $0 $5 $24 EBITDA $49 $47 $68 $59 ($43) $95 Add: Share-Based Compensat
Guardian Pharmacy Services — Investor Presentation (October 2026) on 6ix